title: The use of sulprostone, a prostaglandin E2 derivative, in intrauterine fetal death and therapeutic abortion.
abstract: The prostaglandin E2 derivative Sulprostone was used in the management of intrauterine fetal death and in therapeutic abortion in advanced pregnancy. While with extraamniotic administration there was a success rate of 50% after 24 hours, the rate of success was 86% after intramuscular administration. A cervix-ripening effect was not always observed by means of intracervical injection of Sulprostone. Such pre-treatment of the cervix did not improve the induction-abortion time after intramuscular administration of Sulprostone. Side effects were only slight following Sulprostone.
mesh_terms: D000032:Abortion, Therapeutic; D000293:Adolescent; D000328:Adult; D000650:Amnion; D002584:Cervix Uteri; D015232:Dinoprostone / Q000031:analogs & derivatives*; D005260:Female; D005313:Fetal Death / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D007273:Injections, Intramuscular; D007751:Labor, Induced; D011247:Pregnancy; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D011459:Prostaglandins E, Synthetic; C016767:sulprostone; D015232:Dinoprostone